Neuromuscular Blockade Clinical Trial
Official title:
Comparison Between the Efficacy of Neostigmine Versus Sugammadex Reversal of Rocuronium Induced Neuromuscular Blockade In Paediatric Patients.
A reversal agent is commonly given to improve neuromuscular function after intra-operative
administration of non-depolarizing neuromuscular blocking agents. The administration of
conventional reversal agent neostigmine is associated with many undesirable side effects.
For almost a decade, a new novel drug sugammadex has been used to specifically antagonize
the effect of aminosteroidal neuromuscular blocking agents.
A total of 80 paediatric patients planned for general anaesthesia were divided into two
groups and were given either neostigmine+atropine, or sugammadex for reversal once the
operation had completed.
RESEARCH HYPOTHESIS
1. Sugammadex has a shorter recovery time (from TOF count of 2 or 3 to TOF ratio of more
than 0.9) as compared to neostigmine.
2. Sugammadex has a more stable haemodynamic profile as compared to neostigmine when used
to reverse rocuronium induced neuromuscular blockade in paediatric patients.
3. Sugammadex causes less complications or side effects when used in paediatric patients
as a reversal for rocuronium induced neuromuscular blockade when compared to
neostigmine.
This study was a prospective, double blinded, randomized control study involving 80 selected
paediatric patients undergoing various surgeries under general anaesthesia in the operation
theatre of Hospital University Sains Malaysia (USM), Kubang Kerian.
Sample size The sample size for this study was calculated using Power and Sample Size
Calculation Programme Version 3.0.10.software based on different each respective objectives.
1. To compare the recovery time from Train of four (TOF) count of 2 or 3 to TOF ratio of
more than 0.9 between neostigmine and sugammadex in reversal of rocuronium induced
neuromuscular blockade in paediatric patients.
• For objective 1, 33 participants in each respective groups are needed to detect the
difference of 8 minutes (480 seconds) in time taken to achieve TOF ratio of 0.9
post-administration of reversal agent (SD was 590, according to Olzem Sacan et al) with
90% power, alpha 0.05. 20% is added for drop out participant. Therefore sample size, n
= 33 + (0.2 x 33) = 40 patients.
2. To compare the haemodynamic changes between neostigmine and sugammadex in reversal of
rocuronium induced neuromuscular blockade in paediatric patients.
- For objective 2 (referring to blood pressure), 22 participants in each respective
groups are needed to detect the difference of 10 mmHg in mean arterial blood
pressure 5 minutes post-administration of reversal agent (SD was 10, according to
Olzem Sacan et al) with 90% power, alpha 0.05. 20% is added for drop out
participant. Therefore sample size, n = 22 + (0.2 x 22) = 26 patients.
- For objective 2 (referring to heart rate), 22 participants in each respective
groups are needed to detect the difference of 8 beats per minute in heart rate, 5
minutes post-administration of reversal agent (SD was 8, according to Olzem Sacan
et al) with 90% power, alpha 0.05. 20% is added for drop out participant.
Therefore sample size, n = 22 + (0.2 x 22) = 26 patients.
Therefore the total patients in each group will be 40 patients per group. Total sample size
is 80 patients.
After gaining approval from USM Research Ethics Committee, the study was conducted in the
Operation Theatre Hospital University Sains Malaysia (HUSM).
Parents of patients who fulfilled the inclusion criteria for this study were counselled, and
those who agreed to participate in the study were given full explanation about the study and
written consent was taken.
Randomization Subjects were divided into two groups using allocation sequence generated from
online randomisation software (http://www.randomization.com). These respective allocations
were concealed in sealed envelopes, which were not opened until it was time to administer
the respective reversal agents in the Operation Theatre after completion of surgery.
Patients were randomised to receive either 'Drug A' or 'Drug B' to reverse rocuronium
induced neuromuscular blockade.
The randomization generated by the computer was only known to the anaesthetic assistant
nurse, who is not involved in recruiting patients or carrying out the study.
Blinding This is a double blinded study. There were 2 important measures taken to ensure
this. For this purpose, a specific anaesthetic assistant nurse is allocated before the study
was carried out. This nurse is not involved in recruiting the subjects or carrying out the
study, and is not related to the researcher.
Step 1 : Prior to sample collection, all subjects have already been randomized according to
a sequence derived from online computer randomization. The anaesthetic assistant nurse
prepares 80 envelopes, each respectively numbered 1-80, and 80 cards that will fit into the
envelope, 40 labelled 'A' and 40 labelled 'B'. The cards were inserted into the envelopes
and sealed according to the sequence that was derived from computer randomization. For
example if subject 1 falls under group A, the card labelled 'A' is inserted into the
envelope labelled 1, and firmly sealed. This is continued until all 80 cards have been
inserted into all 80 numbered envelopes according to the determined sequence, all being
firmly sealed. This process is carried out without the presence of the researcher.
Step 2 : On the day of surgery, prior to inducing the patient under general anaesthesia, the
anaesthetic assistant nurse had prepares the reversal agents labelled 'Drug A' and 'Drug B'.
To ensure desired double blinding, both reversal agents had to be diluted into similar
volumes for equivalent dose for each respective drug for reversal of moderate block of
Rocuronium induced neuromuscular blockade (TOF count 2 or 3)
- 1 mg of Atropine (1ml) was mixed with 2.5mg of Neostigmine (1ml) and diluted into 10
mls with Normal Saline 0.9% in a 10ml standard syringe. This would be a solution of 0.1
mg/ml Atropine with 0.25 mg/ml Neostigmine. A normal standard reversal dose for TOF
count of 2 to 3 would be 0.05 mg/kg of Neostigmine with 0.02 mg/kg of Atropine.
Therefore the volume would be 0.2mls per kg.
- 100 mg Sugammadex (1ml) is diluted into 10mls in a standard 10mls syringe with Normal
Saline 0.9%. This will provide a new solution of 10mg/ml. The required dose for
reversal of reversal of Rocuronium induced neuromuscular blockade with a TOF count of 2
or 3 would be 2mg/kg. This will also be equivalent to a volume of 0.2mls per kg.
This process was also done without the presence of the researcher. All medications were
discarded by the end of the day.
Only the anaesthetic assistant nurse is aware which drug, either Neostigmine-Atropine
combination or Sugammadex belongs to either group A (drug A) and group B (drug B), till all
80 samples have been collected. After completion of the study, the researcher is informed
which drug was labelled as 'Drug A' and 'Drug B' respectively.
Study Protocol In the operating room, the patient was put under routine monitoring for
general anaesthesia, including non-invasive blood pressure, electrocardiography, pulse
oxymetry, end tidal carbon dioxide. The TOF Watch Sx, was also placed at the patients hand
appropriately along the ulnar groove to monitor the neurotransmission activity of ulnar
nerve . TOF reading was not taken at this time.
Paediatric Bispectral Index (BIS) monitoring was also placed on the patient's forehead, to
ensure the patient was adequately induced prior to any painful stimulation for example
intravenous access placement or TOF monitoring.
The patient was induced via sevoflurane gaseous induction, with a fresh gas flow rate of 8
litres per min of oxygen. Sevoflurane was dialled between 4 to 6 percent, to ensure
hemodynamic parameters were within acceptable range, and BIS count achieved was 40-50.
Once the patient was fully relaxed and induced, a good functioning appropriate sized
peripheral intravenous access was obtained.
2 mcg/kg of fentanyl was given for analgesia. After administration of fentanyl, the TOF
Watch Sx was calibrated and a baseline TOF reading was taken and recorded.The patient was
paralyzed with 0.6 mg/kg of rocuronium, and intubation of the trachea was done once TOF
count was less than 1.
TOF monitoring was assessed at 15 minute intervals once patient was under general
anaesthesia. Boluses of intravenous rocuronium 0.2 mg/kg was administered intermittently to
maintain a TOF count of 2-3.
The baseline haemodynamic values (blood pressure, heart rate, pulse oxymetry, end tidal
carbon dioxide) were documented prior to induction, post-intubation and the subsequent 15
minutes interval, to obtain a baseline and mean reading. The TOF readings were documented
prior to Rocuronium administration (post-induction), post-intubation, then every 15 minutes
interval, and just prior to reversal.
All patients were given suppositories paracetamol 20-30mg/kg for analgesia. No further
opioids were served other than on induction. Where applicable, regional blocks or local
infiltration at the surgical site were given for analgesia.
Prior to administration of the reversal agent as determined by randomization, it was ensured
that the TOF reading was 2-3.
The following time was taken and recorded :
- from administration of reversal agent to TOF ratio more than 0.9
- from administration of reversal to spontaneous ventilation
- from administration of reversal to adequate ventilation (tidal volume at least 6mls/kg
and adequate respiratory rate for age)
- from administration of reversal to extubation The haemodynamic parameters (blood
pressure, heart rate, pulse oxymetry, respiratory rate, tidal volume, end tidal carbon
dioxide) were documented in 5 minute intervals upon administration of the reversal
agent.
Haemodynamic parameters in the recovery bay (blood pressure, heart rate, pulse oxymetry,
respiratory rate) were also documented.
Patients were also observed for any complications or side effects post-extubation such as
nausea, vomiting, secretions, respiratory distress, etc in the recovery bay.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05558969 -
The Effect of Magnesium Use in Reversal of Neuromuscular Block With Sugammadex
|
N/A | |
Completed |
NCT03168308 -
Sugammadex vs. Neostigmine for Neuromuscular Blockade Reversal in Thoracic Surgical Patients
|
Phase 4 | |
Not yet recruiting |
NCT03978780 -
Erector Spinae Block vs. Placebo Block Study
|
N/A | |
Completed |
NCT02912039 -
Electromyographic Assessment of the TetraGraph in Normal Volunteers
|
||
Completed |
NCT02892045 -
Mindray Neuromuscular Transmission Transducer
|
||
Completed |
NCT03427385 -
Minimum Local Anesthetic Dose for Adductor Canal Block
|
N/A | |
Completed |
NCT01450813 -
The Effect of Neuromuscular Blockade on the Composite Variability Index (CVI) During Laryngoscopy
|
N/A | |
Completed |
NCT00535496 -
Relation Between TOF-Watch® SX and a Peripheral Nerve Stimulator After 4.0 mg.Kg-1 Sugammadex (P05698)
|
Phase 3 | |
Recruiting |
NCT05794503 -
Postoperative Urinary Retention After Reversal of Neuromuscular Block by Neostigmine Versus Sugammadex
|
Early Phase 1 | |
Not yet recruiting |
NCT05993390 -
Pharmacological Reversal of Neuromuscular Blockade in Critically Ill Patients
|
N/A | |
Recruiting |
NCT04609410 -
Bleeding in Laparoscopic Liver Surgery
|
N/A | |
Terminated |
NCT03649672 -
The Validity and Tolerability of Awake Calibration of the TOF Watch SX Monitor
|
N/A | |
Completed |
NCT05474638 -
Comparison of Mechanomyographic 100 Versus 200 Hz 5 Second Tetanic Fade Ratios During Neuromuscular Block Recovery
|
N/A | |
Completed |
NCT05687253 -
Evaluation of Intubation Conditions Following BX1000 or Rocuronium in Subjects Undergoing Surgery
|
Phase 2 | |
Completed |
NCT05120999 -
Comparison of Onset of Neuromuscular Blockade With Electromyographic and Acceleromyographic Monitoring
|
||
Completed |
NCT03608436 -
The Effect of Low Pressure Pneumoperitoneum During Laparoscopic Colorectal Surgery on Early Quality of Recovery
|
Phase 4 | |
Completed |
NCT03572413 -
The Effect of Low Pressure Pneumoperitoneum During Laparoscopic Colorectal Surgery on Innate Immune Homeostasis.
|
Phase 4 | |
Recruiting |
NCT02930629 -
Residual Block in Postoperative Anaesthetic Care Unit
|
N/A | |
Completed |
NCT02932254 -
Magnesium Sulfate Effect Following the Reversal of Neuromuscular Blockade Induced by Rocuronium With Sugammadex
|
Phase 4 | |
Completed |
NCT01828385 -
Effect of Magnesium on the Recovery Time of Neuromuscular Blockade With Sugammadex
|
Phase 4 |